Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesShimon Slavin, Reuven Or, Arnon Nagler et al.|Blood|1998Cited by 1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesShimon Slavin, Reuven Or, Arnon Nagler et al.|Blood|1998Cited by 1.8k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseaseRobert Zeiser, Gèrard Socié, Nikolas von Bubnoff et al.|New England Journal of Medicine|2020Cited by 859
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, David A. Rizzieri et al.|Journal of Clinical Oncology|2013Cited by 439
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantationTobias Feuchtinger, Hermann Einsele, Kathrin Opherk et al.|Blood|2010Cited by 430